Filing identity and reporting period
Important: The supplied filing is Aerovate Therapeutics, Inc.’s Form 10-Q, not a filing for Jade Biosciences, Inc. This summary therefore describes Aerovate. The quarter ended September 30, 2022; the report was signed November 14, 2022.
Business context
Aerovate is a clinical-stage biopharmaceutical company developing AV-101, an inhaled dry-powder formulation of imatinib for pulmonary arterial hypertension (PAH). It had no approved products and had generated no product revenue. Its ongoing IMPAHCT Phase 2b/Phase 3 trial was enrolling adults with PAH.
Financial performance and position
Amounts below are in millions of dollars except per-share data. The company reported no revenue; margins are therefore not meaningful.
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Research and development expense | 10.8 | 3.4 | 26.4 | 9.9 |
| General and administrative expense | 3.4 | 2.8 | 11.0 | 4.8 |
| Total operating expenses | 14.2 | 6.2 | 37.4 | 14.8 |
| Net loss | 13.6 | 6.2 | 36.5 | 14.7 |
| Basic and diluted loss per share | $0.56 | $0.26 | $1.49 | $1.80 |
| Operating cash used | Not provided by quarter | Not provided by quarter | 24.3 | 14.3 |
At September 30, 2022, cash and cash equivalents were $22.4 million and short-term investments were $120.2 million, totaling $142.6 million. Current assets were $145.2 million, current liabilities $7.7 million, and stockholders’ equity $139.1 million. The filing reports no long-term debt; lease liabilities totaled $1.2 million. Accumulated deficit was $72.9 million.
Nine-month investing cash outflow was $7.6 million, mainly reflecting purchases of short-term investments net of sales and maturities. Financing provided $39,000, principally from stock-option exercises, versus $190.7 million in the prior-year period, which included IPO proceeds. Unrealized investment losses contributed $0.7 million to nine-month comprehensive loss.
Material changes versus prior periods
- Q3 operating expenses increased $8.0 million year over year, chiefly because R&D rose $7.4 million as the clinical trial advanced. Management attributed the increase to clinical costs, headcount, and contract manufacturing.
- Nine-month R&D expense rose $16.5 million, primarily reflecting clinical-trial costs, headcount, and manufacturing; lower preclinical costs partly offset the increase.
- Nine-month G&A increased $6.2 million, mainly from public-company costs, professional services, and headcount.
- Interest income increased to $0.6 million for Q3 and $0.9 million for the nine-month period, from minimal amounts in 2021, reflecting income on cash and investments.
- Cash and cash equivalents declined from $54.2 million at December 31, 2021, while short-term investments increased from $113.2 million to $120.2 million. Combined cash and investments decreased from $167.4 million to $142.6 million.
Outlook, risks, and unusual items
- Management estimated that available cash and short-term investments would fund planned operations into the second half of 2025, while cautioning that forecasts depend on uncertain assumptions. The filing also states funds should cover obligations for at least 12 months from filing.
- Management expected substantial operating losses and increased R&D spending for the foreseeable future and said additional capital would be needed to undertake planned activities.
- On August 15, 2022, the company established an at-the-market facility allowing sales of up to $75 million of common stock; no shares had been sold under it by September 30.
- COVID-19-related site activation, staffing, and enrollment delays were affecting the Phase 2b portion of IMPAHCT. The company expected to complete enrollment around mid-2023 and report topline Phase 2b data in Q4 2023 or Q1 2024, but warned timing could slip.
- Key risks include dependence on AV-101 as its sole development candidate; uncertain trial efficacy and tolerability; enrollment and regulatory delays; reliance on third-party manufacturers, suppliers, and CROs; competition; and potential future financing needs and dilution.
- AV-101 had shown generally favorable tolerability in a Phase 1 study of healthy volunteers, but the filing cautions that these results and prior oral-imatinib trial results may not predict PAH-patient outcomes. Oral imatinib had tolerability challenges and did not improve time to clinical worsening in the cited trial.
- The company reported effective disclosure controls as of September 30, 2022, no material changes in internal control over financial reporting during the quarter, and no legal proceedings expected to materially affect its financial position or results.
Investor verification points
- Confirm the intended issuer: the supplied document identifies Aerovate Therapeutics, Inc., despite the request naming Jade Biosciences, Inc.
- Check subsequent IMPAHCT enrollment, Phase 2b results, and any changes to the stated timeline or trial design.
- Review cash burn, investment balances, and updated runway assumptions, including whether the $75 million ATM facility was used after quarter-end.
- Assess whether AV-101 demonstrates safety and efficacy in PAH patients and whether its inhaled formulation addresses the tolerability limitations of oral imatinib.
- Monitor funding needs, potential equity dilution, and dependencies on third-party clinical and manufacturing providers.